Ani Pharmaceuticals Stock Current Valuation
| ANIP Stock | USD 55.01 0.50 0.92% |
Valuation analysis of ANI Pharmaceuticals helps investors to measure ANI Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, ANI Pharmaceuticals' Enterprise Value Over EBITDA is relatively stable compared to the past year. As of 02/27/2025, Enterprise Value Multiple is likely to grow to 11.97, while Enterprise Value is likely to drop slightly above 43 M. Fundamental drivers impacting ANI Pharmaceuticals' valuation include:
Fairly Valued
Today
Please note that ANI Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of ANI Pharmaceuticals is based on 3 months time horizon. Increasing ANI Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
ANI Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 55.01, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 55.01 | Real 55.98 | Target 78.67 | Hype 55.01 | Naive 53.98 |
The intrinsic value of ANI Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence ANI Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of ANI Pharmaceuticals helps investors to forecast how ANI stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ANI Pharmaceuticals more accurately as focusing exclusively on ANI Pharmaceuticals' fundamentals will not take into account other important factors: ANI Pharmaceuticals Company Current Valuation Analysis
ANI Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current ANI Pharmaceuticals Current Valuation | 1.64 B |
Most of ANI Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ANI Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ANI Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for ANI Pharmaceuticals is extremely important. It helps to project a fair market value of ANI Stock properly, considering its historical fundamentals such as Current Valuation. Since ANI Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ANI Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ANI Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, ANI Pharmaceuticals has a Current Valuation of 1.64 B. This is 88.55% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 90.11% higher than that of the company.
ANI Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ANI Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ANI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing ANI Pharmaceuticals by comparing valuation metrics of similar companies.ANI Pharmaceuticals is currently under evaluation in current valuation category among its peers.
ANI Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ANI Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ANI Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
ANI Fundamentals
| Return On Equity | -0.016 | ||||
| Return On Asset | 0.0125 | ||||
| Profit Margin | (0.01) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 1.64 B | ||||
| Shares Outstanding | 21.02 M | ||||
| Shares Owned By Insiders | 11.92 % | ||||
| Shares Owned By Institutions | 88.08 % | ||||
| Number Of Shares Shorted | 2.26 M | ||||
| Price To Earning | 43.35 X | ||||
| Price To Book | 2.83 X | ||||
| Price To Sales | 2.08 X | ||||
| Revenue | 486.82 M | ||||
| Gross Profit | 332.11 M | ||||
| EBITDA | 106.6 M | ||||
| Net Income | 18.78 M | ||||
| Cash And Equivalents | 63.38 M | ||||
| Cash Per Share | 3.89 X | ||||
| Total Debt | 285.67 M | ||||
| Debt To Equity | 0.85 % | ||||
| Current Ratio | 3.35 X | ||||
| Book Value Per Share | 20.74 X | ||||
| Cash Flow From Operations | 118.96 M | ||||
| Short Ratio | 12.82 X | ||||
| Earnings Per Share | (0.47) X | ||||
| Price To Earnings To Growth | 1.06 X | ||||
| Target Price | 78.67 | ||||
| Number Of Employees | 642 | ||||
| Beta | 0.74 | ||||
| Market Capitalization | 1.16 B | ||||
| Total Asset | 904.42 M | ||||
| Retained Earnings | (80.13 M) | ||||
| Working Capital | 374.34 M | ||||
| Current Asset | 192.58 M | ||||
| Current Liabilities | 11.76 M | ||||
| Net Asset | 904.42 M |
About ANI Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ANI Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ANI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ANI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.